FDA Rejects Pfizer's Xeljanz In Plaque Psoriasis
This article was originally published in Scrip
Executive Summary
After the markets closed on Oct. 14, Pfizer Inc. disclosed the FDA had rejected the firm's supplemental new drug application (sNDA) for its JAK inhibitor Xeljanz (tofacitinib citrate) as a treatment for adults with moderate to severe chronic plaque psoriasis.